Fosfomycin Dosing Regimens based on Monte Carlo Simulation for Treated Carbapenem-Resistant Enterobacteriaceae Infection

被引:9
作者
Kanchanasurakit, Sukrit [1 ,2 ,3 ,4 ]
Santimaleeworagun, Wichai [5 ,6 ]
McPherson, Charles E., III [7 ]
Piriyachananusorn, Napacha [2 ]
Boonsong, Benjawan [2 ]
Katwilat, Papanin [8 ]
Saokaew, Surasak [1 ,3 ,4 ,9 ,10 ,11 ]
机构
[1] Univ Phayao, Sch Pharmaceut Sci, Dept Pharmaceut Care, Div Pharm Practice, Phayao, Thailand
[2] Phrae Hosp, Dept Pharm, Div Pharmaceut Care, Phrae, Thailand
[3] Univ Phayao, Ctr Hlth Outcomes Res & Therapeut Safety Cohorts, Sch Pharmaceut Sci, Phayao 56000, Thailand
[4] Univ Phayao, Sch Pharmaceut Sci, Unit Excellence Clin Outcomes Res & Integrat UNIC, Phayao, Thailand
[5] Pharmaceut Initiat Resistant Bacteria & Infect Di, Nakhon Pathom, Thailand
[6] Silpakorn Univ, Fac Pharm, Dept Pharm, Nakhon Pathom, Thailand
[7] Univ Illinois, Coll Pharm, Chicago, IL USA
[8] Phrae Hosp, Dept Med, Div Infect Dis, Phrae, Thailand
[9] Univ Phayao, Sch Pharmaceut Sci, Unit Excellence Herbal Med, Phayao, Thailand
[10] Monash Univ Malaysia, Biomed Res Adv Ctr, Sch Pharm, Biofunct Mol Exploratory Res Grp, Bandar Sunway, Selangor Darul, Malaysia
[11] Monash Univ Malaysia, Jeffrey Cheah Sch Med & Hlth Sci, Microbiome & Bioresource Res Strength, Novel Bacteria & Drug Discovery Res Grp, Bandar Sunway, Selangor Darul, Malaysia
关键词
Fosfomycin; Monte Carlo; Carbapenem-Resistant Enterobacteriaceae; Microbial sensitivity tests; INTRAVENOUS FOSFOMYCIN; PHARMACODYNAMICS; COMBINATION; BACTEREMIA; MEROPENEM; EFFICACY; SYNERGY;
D O I
10.3947/ic.2020.52.4.516
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Background: Infections by Carbapenem-Resistant Enterobacteriaceae (CRE) remain a leading cause of death in critically ill patients. Fosfomycin has been regarded as an alternative therapy for treatment of infections caused by CRE organisms. The purpose of this study is to evaluate clinical outcomes amongst patients with CRE infection who are receiving a fosfomycin dosing regimen using a Monte Carlo simulation and fosfomycin minimum inhibitory concentration (MIC). Materials and Methods: Fosfomycin MIC was defined by the E-test method. We used Fosfomycin pharmacokinetic parameters from a previously published study. The percent of the time period in which the drug concentration exceeded the MIC, or %T>MIC, used in this study were determined to be 70% of T>MIC and 100% of T>MIC, respectively. All dosing regimens were estimated for the probability of target attainment using a Monte Carlo simulation. Results: In this study, we found the MIC's of fosfomycin against CRE isolates ranged from 8 mg/L to 96 mg/L. The total daily dose of fosfomycin ranged from 16 - 24 g and was administered utilizing various fosfomycin dosing regimens to achieve the pharmacokinetic/pharmacodynamic (PK/PD) target in pathogens with a MIC of 32 mg/L for 70%T>MIC and a MIC of 12 mg/L for 100%T>MIC, respectively. For the twelve patients who received the recommended fosfomycin dosing regimen, eleven achieved bacterial eradication for a microbiological cure rate of 91%; and of those patients achieving eradication, two died despite having negative cultures for CRE; the one remaining patient had bacterial persistence. The most commonly observed adverse drug reactions were hypernatremia (3 cases) and hypokalemia (3 cases) and acute kidney injury (3 cases). Conclusion: Our findings suggest fosfomycin has tended to good efficacy when using dosing regimens that achieve the PK/PD target. Nonetheless, further validation of these regimens in larger populations is needed.
引用
收藏
页码:516 / 529
页数:14
相关论文
共 41 条
  • [1] The renoprotective effect of concomitant fosfomycin in the treatment of pulmonary exacerbations in cystic fibrosis
    Al-Aloul, Mohamed
    Nazareth, Dilip
    Walshaw, Martin
    [J]. CLINICAL KIDNEY JOURNAL, 2019, 12 (05) : 652 - 658
  • [2] Pharmacodynamic Evaluation of the Potential Clinical Utility of Fosfomycin and Meropenem in Combination Therapy against KPC-2-Producing Klebsiella pneumoniae
    Albiero, James
    Sy, Sherwin K. B.
    Mazucheli, Josmar
    Caparroz-Assef, Silvana Martins
    Costa, Bruno Buranello
    Borges Alves, Janio Leal
    Gales, Ana Cristina
    Bronharo Tognim, Maria Cristina
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2016, 60 (07) : 4128 - 4139
  • [3] Optimizing intravenous fosfomycin dosing in combination with carbapenems for treatment of Pseudomonas aeruginosa infections in critically ill patients based on pharmacokinetic/pharmacodynamic (PK/PD) simulation
    Asuphon, O.
    Montakantikul, P.
    Houngsaitong, J.
    Kiratisin, P.
    Sonthisombat, P.
    [J]. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2016, 50 : 23 - 29
  • [4] Synergistic activity of fosfomycin-meropenem and fosfomycin-colistin against carbapenem resistant Klebsiella pneumoniae: an in vitro evidence
    Bakthavatchalam, Yamuna Devi
    Shankar, Abirami
    Sethuvel, Dhiviya Prabaa Muthuirulandi
    Asokan, Kalaiarasi
    Kanthan, Kalaiarasi
    Veeraraghavan, Balaji
    [J]. FUTURE SCIENCE OA, 2020, 6 (04):
  • [5] Augmented Renal Clearance in Critically Ill Patients: A Systematic Review
    Bilbao-Meseguer, Idoia
    Rodriguez-Gascon, Alicia
    Barrasa, Helena
    Isla, Arantxazu
    Angeles Solinis, Maria
    [J]. CLINICAL PHARMACOKINETICS, 2018, 57 (09) : 1107 - 1121
  • [6] Predicting efficacy of antiinfectives with pharmacodynamics and Monte Carlo simulation
    Bradley, JS
    Dudley, MN
    Drusano, GL
    [J]. PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2003, 22 (11) : 982 - 992
  • [7] Changpradub D, 2020, SE ASIAN J TROP MED, V51, P263
  • [8] Codjoe Francis S, 2017, Med Sci (Basel), V6, DOI 10.3390/medsci6010001
  • [9] De Rosa FG, 2015, FUTURE MICROBIOL, V10, P285, DOI [10.2217/FMB.14.121, 10.2217/fmb.14.121]
  • [10] Pharmacodynamics of Fosfomycin: Insights into Clinical Use for Antimicrobial Resistance
    Docobo-Perez, F.
    Drusano, G. L.
    Johnson, A.
    Goodwin, J.
    Whalley, S.
    Ramos-Martin, V.
    Ballestero-Tellez, M.
    Rodriguez-Martinez, J. M.
    Conejo, M. C.
    van Guilder, M.
    Rodriguez-Bano, J.
    Pascual, A.
    Hope, W. W.
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2015, 59 (09) : 5602 - 5610